Harry J. Leonhardt
2022 - Poseida Therapeutics
In 2022, Harry J. Leonhardt earned a total compensation of $978.3K as General Counsel, Chief Compliance Officer and Corporate Secretary at Poseida Therapeutics, a 32% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $188,690 |
---|---|
Option Awards | $177,109 |
Salary | $428,833 |
Stock Awards | $171,000 |
Other | $12,710 |
Total | $978,342 |
Leonhardt received $428.8K in salary, accounting for 44% of the total pay in 2022.
Leonhardt also received $188.7K in non-equity incentive plan, $177.1K in option awards, $171K in stock awards and $12.7K in other compensation.
Rankings
In 2022, Harry J. Leonhardt's compensation ranked 3,073rd out of 5,733 executives tracked by ExecPay. In other words, Leonhardt earned more than 46.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,073 | 46th |
Manufacturing | 1,731 | 45th |
Chemicals And Allied Products | 815 | 42nd |
Drugs | 761 | 42nd |
Biological Products, Except Diagnostic Substances | 185 | 36th |
Leonhardt's colleagues
We found three more compensation records of executives who worked with Harry J. Leonhardt at Poseida Therapeutics in 2022.
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019